An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.
• Adequate bone marrow and other vital organ functions
• Adequate liver function tests
• HR-positive or HER2-negative solid tumor patients
Locations
Other Locations
Australia
Ballarat Base Hospital
RECRUITING
Ballarat
Southern Highlands Private Hospital
RECRUITING
Bowral
Lyell McEwin Hospital
RECRUITING
Elizabeth Vale
Frankston Hospital
RECRUITING
Frankston
GenesisCare Frenchs Forest
RECRUITING
Sydney
GenesisCare St Leonards
RECRUITING
Sydney
Contact Information
Primary
Kathy You
kathyyou@atridia.com
+61 02 9299 0433
Backup
Ravi Patel
ravi.patel@atridia.com
+61 452 363 506
Time Frame
Start Date: 2026-05-15
Estimated Completion Date: 2027-11-10
Participants
Target number of participants: 15
Treatments
Experimental: HRS-6209 Capsules and fulvestrant injection
Related Therapeutic Areas
Sponsors
Leads: Atridia Pty Ltd.